Literature DB >> 19226610

RET-mediated gene expression pattern is affected by isoform but not oncogenic mutation.

Jessica G Hickey1, Shirley M Myers, Xuefei Tian, Shu Jun Zhu, Julie L V Shaw, Scott D Andrew, Douglas S Richardson, Julia Brettschneider, Lois M Mulligan.   

Abstract

The inherited cancer syndrome multiple endocrine neoplasia type 2 (MEN 2) is caused by mutations of the RET receptor tyrosine kinase and is characterized by medullary thyroid carcinoma. MEN 2 subtypes have distinct mutational spectrums and vary in severity. The most severe disease subtype, MEN 2B, is associated with a specific RET mutation (M918T) that has been predicted to alter downstream signaling and target gene expression patterns. We used gene expression microarray analysis to identify target genes modulated by RET. We compared two oncogenic RET mutants, associated with MEN 2A (2ARET) or MEN 2B (2BRET) disease subtypes, that are predicted to have distinct downstream target genes. We showed that overall, 2ARET and 2BRET modulated genes with similar functional ontologies. Further, when we validated our microarray data by quantitative real time PCR, we did not detect major differences in gene expression associated with these mutants when differences in receptor activity levels were considered. We did, however, detect differences in gene expression induced by two RET COOH-terminal isoforms, RET9 and RET51, irrespective of the RET form present (wildtype, 2ARET, or 2BRET). Our data suggest that similar transcriptional programs contribute to all forms of MEN 2 but that differences in target gene expression may contribute to developmental pattern differences observed between RET isoforms. Copyright 2009 Wiley-Liss,Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19226610     DOI: 10.1002/gcc.20653

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  6 in total

1.  RET isoforms contribute differentially to invasive processes in pancreatic ductal adenocarcinoma.

Authors:  Eric Y Lian; Brandy D Hyndman; Serisha Moodley; Sarah M Maritan; Lois M Mulligan
Journal:  Oncogene       Date:  2020-09-03       Impact factor: 9.867

2.  Multiple Roles of Ret Signalling During Enteric Neurogenesis.

Authors:  Dipa Natarajan; Conor McCann; Justine Dattani; Vassilis Pachnis; Nikhil Thapar
Journal:  Front Mol Neurosci       Date:  2022-05-27       Impact factor: 6.261

3.  Alternative splicing results in RET isoforms with distinct trafficking properties.

Authors:  Douglas S Richardson; David M Rodrigues; Brandy D Hyndman; Mathieu J F Crupi; Adrian C Nicolescu; Lois M Mulligan
Journal:  Mol Biol Cell       Date:  2012-08-08       Impact factor: 4.138

Review 4.  RET in breast cancer: pathogenic implications and mechanisms of drug resistance.

Authors:  Cristiana Lo Nigro; Marta Rusmini; Isabella Ceccherini
Journal:  Cancer Drug Resist       Date:  2019-12-19

Review 5.  Molecular mechanisms of RET receptor-mediated oncogenesis in multiple endocrine neoplasia 2.

Authors:  Simona M Wagner; ShuJun Zhu; Adrian C Nicolescu; Lois M Mulligan
Journal:  Clinics (Sao Paulo)       Date:  2012       Impact factor: 2.365

6.  Genetic and epigenetic factors affect RET gene expression in breast cancer cell lines and influence survival in patients.

Authors:  Paola Griseri; Ornella Garrone; Alessandra Lo Sardo; Martino Monteverde; Marta Rusmini; Federica Tonissi; Marco Merlano; Paolo Bruzzi; Cristiana Lo Nigro; Isabella Ceccherini
Journal:  Oncotarget       Date:  2016-05-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.